Associated Papers
Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.
Yusoff YM et al.
The Malaysian Journal of Pathology, 2024
Chronic myeloid leukemia kinase domain mutations: A retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII Hospital, KwaZulu-Natal, South Africa.
Benjamin C et al.
Health Science Reports, 2023
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-ABL1
Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.
De Roeck L et al.
Hematology (amsterdam, Netherlands), 2018
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
Korfi K et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2015
25712455 (PubMed )
Supplement: supp_mdv110_mdv110supp.docx
Select a paper to view details